PFKM Antibody - #DF7362

(2)   (4)  
Product: PFKM Antibody
Catalog: DF7362
Description: Rabbit polyclonal antibody to PFKM
Application: WB IHC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 85kDa; 85kD(Calculated).
Uniprot: P08237
RRID: AB_2839300

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(88%)
Clonality:
Polyclonal
Specificity:
PFKM Antibody detects endogenous levels of total PFKM.
RRID:
AB_2839300
Cite Format: Affinity Biosciences Cat# DF7362, RRID:AB_2839300.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

6 Phosphofructokinase Muscle Type; 6-phosphofructokinase; 6-phosphofructokinase muscle type; EC 2.7.1.1; EC 2.7.1.11; GSD7; K6PF_HUMAN; MGC8699; muscle type; PFK, muscle type; PFK-A; PFKA; PFKL; PFKM; PFKP; PFKX; Phosphofructo 1 Kinase Isozyme A; Phosphofructo-1-kinase isozyme A; Phosphofructokinase 1; Phosphofructokinase M; Phosphofructokinase, muscle; Phosphofructokinase, muscle type; Phosphofructokinase, polypeptide X; Phosphofructokinase-M; Phosphohexokinase;

Immunogens

Immunogen:

A synthesized peptide derived from human PFKM, corresponding to a region within N-terminal amino acids.

Uniprot:

P08237(PFKAM_HUMAN) >>Visit HPA database.

Gene(ID):
PFKM(5213)
Description:
Three phosphofructokinase isozymes exist in humans: muscle, liver and platelet. These isozymes function as subunits of the mammalian tetramer phosphofructokinase, which catalyzes the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate. Tetramer composition varies depending on tissue type. This gene encodes the muscle-type isozyme. Mutations in this gene have been associated with glycogen storage disease type VII, also known as Tarui disease. Alternatively spliced transcript variants have been described.
Sequence:
MTHEEHHAAKTLGIGKAIAVLTSGGDAQGMNAAVRAVVRVGIFTGARVFFVHEGYQGLVDGGDHIKEATWESVSMMLQLGGTVIGSARCKDFREREGRLRAAYNLVKRGITNLCVIGGDGSLTGADTFRSEWSDLLSDLQKAGKITDEEATKSSYLNIVGLVGSIDNDFCGTDMTIGTDSALHRIMEIVDAITTTAQSHQRTFVLEVMGRHCGYLALVTSLSCGADWVFIPECPPDDDWEEHLCRRLSETRTRGSRLNIIIVAEGAIDKNGKPITSEDIKNLVVKRLGYDTRVTVLGHVQRGGTPSAFDRILGSRMGVEAVMALLEGTPDTPACVVSLSGNQAVRLPLMECVQVTKDVTKAMDEKKFDEALKLRGRSFMNNWEVYKLLAHVRPPVSKSGSHTVAVMNVGAPAAGMNAAVRSTVRIGLIQGNRVLVVHDGFEGLAKGQIEEAGWSYVGGWTGQGGSKLGTKRTLPKKSFEQISANITKFNIQGLVIIGGFEAYTGGLELMEGRKQFDELCIPFVVIPATVSNNVPGSDFSVGADTALNTICTTCDRIKQSAAGTKRRVFIIETMGGYCGYLATMAGLAAGADAAYIFEEPFTIRDLQANVEHLVQKMKTTVKRGLVLRNEKCNENYTTDFIFNLYSEEGKGIFDSRKNVLGHMQQGGSPTPFDRNFATKMGAKAMNWMSGKIKESYRNGRIFANTPDSGCVLGMRKRALVFQPVAELKDQTDFEHRIPKEQWWLKLRPILKILAKYEIDLDTSDHAHLEHITRKRSGEAAV

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Xenopus
88
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis.

PTMs:

GlcNAcylation decreases enzyme activity.

Subcellular Location:

Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Family&Domains:

Belongs to the phosphofructokinase type A (PFKA) family. ATP-dependent PFK group I subfamily. Eukaryotic two domain clade 'E' sub-subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > RNA degradation.

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Metabolism > Carbohydrate metabolism > Glycolysis / Gluconeogenesis.

· Metabolism > Carbohydrate metabolism > Pentose phosphate pathway.

· Metabolism > Carbohydrate metabolism > Fructose and mannose metabolism.

· Metabolism > Carbohydrate metabolism > Galactose metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Carbon metabolism.

· Metabolism > Global and overview maps > Biosynthesis of amino acids.

References

1). Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer. PHARMACOLOGICAL RESEARCH, 2021 (PubMed: 33992797) [IF=9.1]

Application: WB    Species: human    Sample: MIA PaCa-2 cells

Fig. 4. | Bruceine A induces cell growth inhibition and apoptosis via PFKFB4-mediated glycolysis in MIA PaCa-2 cells. (C) MIA PaCa-2 cells were treated with various concentrations of bruceine A for 24 h. Protein levels of GLUT1, HK2, PFKFB4, PFKM, PKM2, LDHA, and β-actin were detected. β-actin was served was as control. Results were expressed as means ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus control cultured with 0.1% DMSO by one-way ANOVA and post hoc tests.
2). Novel long non‐coding RNA CYB561‐5 promotes aerobic glycolysis and tumorigenesis by interacting with basigin in non‐small cell lung cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022 (PubMed: 35064752) [IF=5.3]

Application: WB    Species: human    Sample: H1299 cells

FIGURE 4| Lnc-CYB561-5 promotes aerobic glycolysis in vivo. (G–I) Relative mRNA and protein expression levels of Pfk1, Hk1, Hk2, Eno1, G6pi and Glut1 in H1299 cells. *p < 0.05, **p < 0.01, ***p < 0.001,NS, p > 0.05 vs. the sh-Ctrl group, n = 5. Data are presented as means ± SEM. Multiple group comparisons were performed using one-way ANOVA followed by Tukey's post hoc test

Application: WB    Species: Human    Sample: H1299 cells

FIGURE 4 Lnc‐CYB561‐5 promotes aerobic glycolysis in vivo. (A) Cluster analysis of differentially expressed mRNAs in H1299 cells treated with the lnc‐CYB561‐5 knockdown. (B) The top 20 GO enrichment of significantly upregulated genes (fold change > 2, p < 0.05, top 100). (C) Heatmap depicting relative expression of known genes related to glycolysis. (D and E) Measurement of ECARO and CR in H1299 cells treated with the lnc‐CYB561‐5 knockdown. (F) Relative glycolysis rates in H1299 cells, as judged by Seahorse analyses. (G–I) Relative mRNA and protein expression levels of Pfk1, Hk1, Hk2, Eno1, G6pi and Glut1 in H1299 cells. *p < 0.05, **p < 0.01, ***p < 0.001, NS, p > 0.05 vs. the sh‐Ctrl group, n = 5. Data are presented as means ± SEM. Multiple group comparisons were performed using one‐way ANOVA followed by Tukey's post hoc test

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.